 Edward Dempsey
Concepts (332)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neprilysin | 6 | 2017 | 47 | 2.200 |
Why?
| | Muscle, Smooth, Vascular | 22 | 2017 | 452 | 2.110 |
Why?
| | Protein Kinase C | 15 | 2007 | 252 | 1.680 |
Why?
| | Pulmonary Artery | 26 | 2020 | 1134 | 1.620 |
Why?
| | rho GTP-Binding Proteins | 2 | 2020 | 56 | 1.120 |
Why?
| | Hypoxia | 18 | 2021 | 1199 | 1.110 |
Why?
| | Pulmonary Circulation | 7 | 2009 | 430 | 0.880 |
Why?
| | Isoenzymes | 9 | 2007 | 299 | 0.670 |
Why?
| | Hypertension, Pulmonary | 12 | 2021 | 1980 | 0.630 |
Why?
| | Lung | 11 | 2021 | 4109 | 0.590 |
Why?
| | Evans Blue | 1 | 2018 | 8 | 0.570 |
Why?
| | Capillary Permeability | 1 | 2018 | 134 | 0.540 |
Why?
| | Cell Division | 25 | 2009 | 766 | 0.530 |
Why?
| | Protein Kinase C-epsilon | 3 | 2005 | 23 | 0.510 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2019 | 266 | 0.500 |
Why?
| | Muscle Proteins | 1 | 2017 | 244 | 0.470 |
Why?
| | Blood Vessels | 3 | 2016 | 171 | 0.460 |
Why?
| | Endothelium, Vascular | 2 | 2020 | 965 | 0.390 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 31 | 0.380 |
Why?
| | Aging | 4 | 2020 | 1966 | 0.370 |
Why?
| | Mice, Knockout | 6 | 2017 | 3125 | 0.360 |
Why?
| | Animals | 44 | 2021 | 38109 | 0.360 |
Why?
| | Animals, Newborn | 10 | 2007 | 902 | 0.340 |
Why?
| | Airway Remodeling | 1 | 2010 | 64 | 0.310 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2017 | 923 | 0.300 |
Why?
| | Cattle | 16 | 2002 | 1000 | 0.270 |
Why?
| | Fibroblasts | 7 | 2019 | 1034 | 0.240 |
Why?
| | Mice | 14 | 2018 | 18365 | 0.230 |
Why?
| | Endothelin-1 | 2 | 2017 | 184 | 0.220 |
Why?
| | Protein Kinases | 1 | 2007 | 315 | 0.220 |
Why?
| | Signal Transduction | 7 | 2020 | 5233 | 0.210 |
Why?
| | Enzyme Activation | 5 | 2017 | 768 | 0.210 |
Why?
| | Lung Neoplasms | 11 | 2012 | 2642 | 0.200 |
Why?
| | rho-Associated Kinases | 2 | 2019 | 83 | 0.200 |
Why?
| | Cells, Cultured | 12 | 2017 | 4155 | 0.190 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2002 | 55 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 3 | 2012 | 85 | 0.190 |
Why?
| | Insulin-Like Growth Factor I | 3 | 1997 | 319 | 0.180 |
Why?
| | Lung Diseases | 2 | 2007 | 787 | 0.180 |
Why?
| | Vascular Remodeling | 2 | 2021 | 205 | 0.180 |
Why?
| | Vasoconstriction | 1 | 2002 | 217 | 0.170 |
Why?
| | Growth Substances | 4 | 1997 | 140 | 0.170 |
Why?
| | Cell Movement | 3 | 2017 | 965 | 0.170 |
Why?
| | Tetradecanoylphorbol Acetate | 5 | 1997 | 153 | 0.170 |
Why?
| | Mice, Inbred C57BL | 5 | 2017 | 5997 | 0.170 |
Why?
| | Butyrates | 1 | 2021 | 67 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2020 | 167 | 0.160 |
Why?
| | Metabolic Diseases | 1 | 2021 | 114 | 0.160 |
Why?
| | Mitogens | 2 | 1997 | 55 | 0.160 |
Why?
| | Forkhead Box Protein O3 | 1 | 2020 | 18 | 0.160 |
Why?
| | Phenotype | 5 | 2017 | 3164 | 0.150 |
Why?
| | Platelet-Derived Growth Factor | 3 | 1997 | 90 | 0.150 |
Why?
| | Vasa Vasorum | 1 | 2020 | 37 | 0.150 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 153 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 233 | 0.150 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2019 | 76 | 0.140 |
Why?
| | Genotype | 2 | 2017 | 1835 | 0.140 |
Why?
| | Cellular Microenvironment | 1 | 2019 | 94 | 0.140 |
Why?
| | Pulmonary Alveoli | 2 | 2012 | 383 | 0.140 |
Why?
| | Thymidine | 5 | 1996 | 60 | 0.140 |
Why?
| | Metabolome | 1 | 2021 | 384 | 0.140 |
Why?
| | ets-Domain Protein Elk-1 | 1 | 2017 | 11 | 0.140 |
Why?
| | Smooth Muscle Myosins | 1 | 2017 | 7 | 0.140 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2017 | 78 | 0.130 |
Why?
| | Actins | 3 | 2017 | 425 | 0.130 |
Why?
| | Microfilament Proteins | 1 | 2017 | 136 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2019 | 251 | 0.120 |
Why?
| | Calcium-Binding Proteins | 1 | 2017 | 220 | 0.120 |
Why?
| | Substance P | 1 | 2016 | 39 | 0.120 |
Why?
| | Doxycycline | 1 | 2016 | 62 | 0.120 |
Why?
| | Duodenum | 1 | 2016 | 77 | 0.120 |
Why?
| | Chronic Disease | 6 | 2009 | 1813 | 0.120 |
Why?
| | Neovascularization, Pathologic | 5 | 2020 | 286 | 0.120 |
Why?
| | Pneumonia | 1 | 2021 | 631 | 0.110 |
Why?
| | Sleep Apnea Syndromes | 2 | 2013 | 97 | 0.110 |
Why?
| | Uterus | 3 | 2006 | 226 | 0.110 |
Why?
| | Carcinogens | 2 | 2012 | 123 | 0.110 |
Why?
| | In Vitro Techniques | 5 | 2007 | 1048 | 0.110 |
Why?
| | Myocardium | 1 | 2019 | 939 | 0.100 |
Why?
| | Sputum | 3 | 2005 | 308 | 0.100 |
Why?
| | Cell Communication | 1 | 1996 | 324 | 0.100 |
Why?
| | Humans | 30 | 2021 | 144957 | 0.100 |
Why?
| | Estradiol | 2 | 1997 | 533 | 0.100 |
Why?
| | Enzyme Inhibitors | 4 | 2002 | 826 | 0.100 |
Why?
| | Endothelial Cells | 3 | 2021 | 870 | 0.090 |
Why?
| | Blotting, Western | 3 | 2012 | 1187 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 1997 | 906 | 0.090 |
Why?
| | Quinazolines | 2 | 2012 | 266 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2017 | 2499 | 0.090 |
Why?
| | Piperidines | 2 | 2012 | 217 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2609 | 0.090 |
Why?
| | Bronchoscopy | 5 | 2009 | 227 | 0.090 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2005 | 269 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2185 | 0.080 |
Why?
| | DNA Primers | 2 | 2009 | 512 | 0.080 |
Why?
| | Somatomedins | 1 | 1990 | 28 | 0.080 |
Why?
| | Arteries | 2 | 2006 | 259 | 0.080 |
Why?
| | Carcinoma in Situ | 3 | 2005 | 44 | 0.080 |
Why?
| | Precancerous Conditions | 3 | 2004 | 166 | 0.080 |
Why?
| | Maleimides | 3 | 2000 | 21 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2171 | 0.070 |
Why?
| | Isotretinoin | 1 | 2009 | 26 | 0.070 |
Why?
| | Tocopherols | 1 | 2009 | 30 | 0.070 |
Why?
| | ErbB Receptors | 1 | 2012 | 629 | 0.070 |
Why?
| | Blood Pressure | 3 | 2021 | 1769 | 0.070 |
Why?
| | Cell Hypoxia | 3 | 1999 | 247 | 0.070 |
Why?
| | Biomarkers | 1 | 2020 | 4275 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2005 | 642 | 0.070 |
Why?
| | Biomarkers, Tumor | 3 | 2012 | 1322 | 0.070 |
Why?
| | Galectin 1 | 1 | 2006 | 2 | 0.060 |
Why?
| | Genes, ras | 2 | 1997 | 96 | 0.060 |
Why?
| | Bronchi | 2 | 2000 | 267 | 0.060 |
Why?
| | Female | 17 | 2012 | 78376 | 0.060 |
Why?
| | Hyperoxia | 1 | 2007 | 99 | 0.060 |
Why?
| | Videotape Recording | 1 | 2006 | 37 | 0.060 |
Why?
| | Thiazolidinediones | 1 | 2006 | 139 | 0.060 |
Why?
| | Heart Failure | 1 | 2019 | 2323 | 0.060 |
Why?
| | Smoking | 4 | 2009 | 1472 | 0.060 |
Why?
| | Male | 10 | 2018 | 72406 | 0.060 |
Why?
| | Indoles | 3 | 2000 | 501 | 0.060 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2021 | 150 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 2540 | 0.060 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2005 | 162 | 0.060 |
Why?
| | DNA | 4 | 1997 | 1464 | 0.060 |
Why?
| | Blood | 2 | 1995 | 109 | 0.050 |
Why?
| | Rats | 4 | 2021 | 5614 | 0.050 |
Why?
| | Endothelins | 2 | 1996 | 63 | 0.050 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2005 | 204 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4569 | 0.050 |
Why?
| | Calcium | 2 | 2002 | 1184 | 0.050 |
Why?
| | Drug Synergism | 3 | 1996 | 357 | 0.050 |
Why?
| | Guinea Pigs | 3 | 2006 | 159 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 1997 | 636 | 0.050 |
Why?
| | Hemodynamics | 1 | 2009 | 1121 | 0.050 |
Why?
| | Drug Delivery Systems | 1 | 2007 | 381 | 0.050 |
Why?
| | Shaw Potassium Channels | 1 | 2002 | 4 | 0.050 |
Why?
| | Potassium Chloride | 1 | 2002 | 40 | 0.050 |
Why?
| | Stem Cells | 1 | 2007 | 627 | 0.050 |
Why?
| | Fetus | 2 | 1997 | 803 | 0.050 |
Why?
| | Potassium Channel Blockers | 1 | 2002 | 47 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 460 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2010 | 3608 | 0.050 |
Why?
| | Angiotensin II | 1 | 2002 | 97 | 0.050 |
Why?
| | Nitric Oxide Synthase | 1 | 2002 | 235 | 0.040 |
Why?
| | Potassium Channels | 1 | 2002 | 145 | 0.040 |
Why?
| | Tunica Media | 2 | 1998 | 37 | 0.040 |
Why?
| | Urethane | 2 | 2012 | 43 | 0.040 |
Why?
| | Protein Kinase C beta | 2 | 2000 | 21 | 0.040 |
Why?
| | Gene Deletion | 1 | 2002 | 389 | 0.040 |
Why?
| | Systole | 1 | 2021 | 178 | 0.040 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2197 | 0.040 |
Why?
| | Fluorescence | 1 | 2001 | 161 | 0.040 |
Why?
| | Tight Junctions | 1 | 2021 | 81 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 256 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2006 | 780 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2005 | 897 | 0.040 |
Why?
| | Microvessels | 1 | 2021 | 99 | 0.040 |
Why?
| | Receptors, Purinergic P2Y | 1 | 2020 | 9 | 0.040 |
Why?
| | Macrophages | 2 | 2021 | 1511 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2009 | 2365 | 0.040 |
Why?
| | Cytokines | 2 | 2021 | 2065 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 674 | 0.040 |
Why?
| | GTPase-Activating Proteins | 1 | 2019 | 82 | 0.040 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2019 | 64 | 0.040 |
Why?
| | Trans-Activators | 1 | 2001 | 405 | 0.040 |
Why?
| | Aged | 6 | 2010 | 25947 | 0.040 |
Why?
| | Light | 1 | 2001 | 411 | 0.030 |
Why?
| | Up-Regulation | 1 | 2021 | 852 | 0.030 |
Why?
| | Immune System | 1 | 2019 | 179 | 0.030 |
Why?
| | Leukocytes | 1 | 2019 | 295 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2020 | 381 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2019 | 348 | 0.030 |
Why?
| | Culture Media, Serum-Free | 1 | 1997 | 42 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2020 | 437 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1997 | 39 | 0.030 |
Why?
| | Aorta | 2 | 2001 | 430 | 0.030 |
Why?
| | Oxygen | 1 | 2002 | 995 | 0.030 |
Why?
| | Protein Kinase C-alpha | 1 | 1997 | 37 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2020 | 498 | 0.030 |
Why?
| | Neoplasms | 1 | 2013 | 2884 | 0.030 |
Why?
| | Ischemia | 1 | 2000 | 421 | 0.030 |
Why?
| | Organ Specificity | 1 | 1997 | 313 | 0.030 |
Why?
| | Pregnancy, Animal | 1 | 1997 | 52 | 0.030 |
Why?
| | Bronchial Neoplasms | 1 | 1996 | 15 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 116 | 0.030 |
Why?
| | Rabbits | 1 | 1997 | 648 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2001 | 1990 | 0.030 |
Why?
| | Microcirculation | 2 | 2007 | 138 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2021 | 760 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 451 | 0.030 |
Why?
| | Species Specificity | 1 | 1997 | 574 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2001 | 749 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 621 | 0.030 |
Why?
| | Blood Physiological Phenomena | 1 | 1996 | 12 | 0.030 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 14 | 0.030 |
Why?
| | Tritium | 1 | 1996 | 68 | 0.030 |
Why?
| | Point Mutation | 1 | 1997 | 243 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 2032 | 0.030 |
Why?
| | Neoplasms, Second Primary | 1 | 1997 | 100 | 0.030 |
Why?
| | Rats, Inbred Strains | 1 | 1996 | 321 | 0.030 |
Why?
| | Middle Aged | 5 | 2010 | 35928 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 1996 | 409 | 0.030 |
Why?
| | Protein Precursors | 1 | 1996 | 137 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 556 | 0.030 |
Why?
| | Catalysis | 1 | 1995 | 322 | 0.030 |
Why?
| | Subcellular Fractions | 1 | 1994 | 74 | 0.030 |
Why?
| | Adenosine Diphosphate | 1 | 1994 | 84 | 0.030 |
Why?
| | Flow Cytometry | 2 | 1996 | 1173 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1054 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1822 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1997 | 1371 | 0.030 |
Why?
| | Poly I-C | 1 | 1994 | 57 | 0.030 |
Why?
| | Blood Proteins | 1 | 1996 | 249 | 0.030 |
Why?
| | Exercise | 1 | 2006 | 2201 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 1996 | 494 | 0.030 |
Why?
| | Endothelin Receptor Antagonists | 1 | 1993 | 62 | 0.020 |
Why?
| | Young Adult | 1 | 2010 | 14126 | 0.020 |
Why?
| | Quality of Life | 1 | 2006 | 3192 | 0.020 |
Why?
| | Hyperplasia | 2 | 2006 | 174 | 0.020 |
Why?
| | Complement Factor B | 1 | 1994 | 106 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 1996 | 444 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 1996 | 457 | 0.020 |
Why?
| | Methylcholanthrene | 1 | 2012 | 21 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2012 | 36 | 0.020 |
Why?
| | Risk Factors | 5 | 2009 | 10792 | 0.020 |
Why?
| | Serotonin | 1 | 1994 | 294 | 0.020 |
Why?
| | Extracellular Matrix | 2 | 2006 | 553 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 200 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1993 | 275 | 0.020 |
Why?
| | Apoptosis | 1 | 2000 | 2430 | 0.020 |
Why?
| | Phorbol 12,13-Dibutyrate | 1 | 1991 | 8 | 0.020 |
Why?
| | Cell Count | 2 | 2006 | 321 | 0.020 |
Why?
| | Aerobiosis | 1 | 1991 | 22 | 0.020 |
Why?
| | Time Factors | 2 | 2007 | 7183 | 0.020 |
Why?
| | Dimethyl Sulfoxide | 1 | 1991 | 41 | 0.020 |
Why?
| | Anaerobiosis | 1 | 1991 | 64 | 0.020 |
Why?
| | Pregnancy | 3 | 2006 | 7191 | 0.020 |
Why?
| | Blood Platelets | 1 | 1994 | 400 | 0.020 |
Why?
| | Adolescent | 1 | 2010 | 22453 | 0.020 |
Why?
| | Tumor Cells, Cultured | 3 | 1996 | 919 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2007 | 6434 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2012 | 220 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 90 | 0.020 |
Why?
| | Biopsy | 2 | 2005 | 1077 | 0.020 |
Why?
| | Protein Binding | 1 | 1996 | 2276 | 0.020 |
Why?
| | DNA Replication | 1 | 1991 | 251 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 549 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 627 | 0.020 |
Why?
| | RNA, Messenger | 1 | 1996 | 2832 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2007 | 88 | 0.020 |
Why?
| | Kinetics | 1 | 1991 | 1629 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2010 | 434 | 0.020 |
Why?
| | Rats, Inbred WKY | 1 | 2006 | 37 | 0.020 |
Why?
| | Elastin | 1 | 2006 | 79 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 72 | 0.020 |
Why?
| | Codon | 2 | 1997 | 94 | 0.020 |
Why?
| | PPAR gamma | 1 | 2006 | 177 | 0.010 |
Why?
| | Serum | 1 | 2006 | 59 | 0.010 |
Why?
| | Vascular Resistance | 1 | 2006 | 367 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2006 | 529 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 2009 | 8279 | 0.010 |
Why?
| | Collagen | 1 | 2006 | 456 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 970 | 0.010 |
Why?
| | Sheep | 1 | 2006 | 880 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1997 | 1054 | 0.010 |
Why?
| | Teaching | 1 | 2006 | 236 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 333 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 2005 | 509 | 0.010 |
Why?
| | Vital Capacity | 1 | 2004 | 290 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2010 | 931 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1524 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2004 | 449 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2191 | 0.010 |
Why?
| | Epithelial Cells | 2 | 2001 | 1126 | 0.010 |
Why?
| | Activities of Daily Living | 1 | 2006 | 441 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1141 | 0.010 |
Why?
| | Gestational Age | 1 | 2006 | 975 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2007 | 410 | 0.010 |
Why?
| | Patient Compliance | 1 | 2006 | 589 | 0.010 |
Why?
| | Metaplasia | 1 | 2001 | 57 | 0.010 |
Why?
| | CREB-Binding Protein | 1 | 2001 | 34 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2001 | 312 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 2001 | 370 | 0.010 |
Why?
| | Adaptation, Psychological | 1 | 2006 | 717 | 0.010 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2000 | 43 | 0.010 |
Why?
| | Loss of Heterozygosity | 1 | 2000 | 52 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 49 | 0.010 |
Why?
| | Ki-67 Antigen | 1 | 2000 | 117 | 0.010 |
Why?
| | Carcinoma | 1 | 2001 | 228 | 0.010 |
Why?
| | Airway Obstruction | 1 | 2001 | 162 | 0.010 |
Why?
| | Fibrosis | 1 | 2002 | 548 | 0.010 |
Why?
| | Risk | 1 | 2001 | 911 | 0.010 |
Why?
| | Cell Death | 1 | 2000 | 383 | 0.010 |
Why?
| | Prevalence | 1 | 2005 | 2836 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 1997 | 1182 | 0.010 |
Why?
| | Mitotic Index | 1 | 1997 | 25 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1997 | 79 | 0.010 |
Why?
| | Cytoskeletal Proteins | 1 | 1997 | 156 | 0.010 |
Why?
| | Tunica Intima | 1 | 1997 | 79 | 0.010 |
Why?
| | Mammals | 1 | 1999 | 293 | 0.010 |
Why?
| | Chromosome Banding | 1 | 1996 | 17 | 0.010 |
Why?
| | Myosins | 1 | 1997 | 136 | 0.010 |
Why?
| | Ploidies | 1 | 1996 | 20 | 0.010 |
Why?
| | Karyotyping | 1 | 1996 | 106 | 0.010 |
Why?
| | Ligases | 1 | 1996 | 37 | 0.010 |
Why?
| | Ovariectomy | 1 | 1997 | 162 | 0.010 |
Why?
| | Bronchoalveolar Lavage | 1 | 1996 | 89 | 0.010 |
Why?
| | Comorbidity | 1 | 2001 | 1660 | 0.010 |
Why?
| | Heparin | 1 | 1997 | 244 | 0.010 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2000 | 531 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2000 | 1718 | 0.010 |
Why?
| | Immunophenotyping | 1 | 1996 | 322 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 1997 | 514 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2001 | 1496 | 0.010 |
Why?
| | HeLa Cells | 1 | 1996 | 650 | 0.010 |
Why?
| | Calcimycin | 1 | 1994 | 36 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 1994 | 171 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1994 | 251 | 0.010 |
Why?
| | Interferon-beta | 1 | 1994 | 92 | 0.010 |
Why?
| | Cell Survival | 1 | 1996 | 1098 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2006 | 6053 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 1997 | 1465 | 0.010 |
Why?
| | Mass Screening | 1 | 2001 | 1348 | 0.010 |
Why?
| | Prognosis | 1 | 2001 | 4293 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1994 | 193 | 0.010 |
Why?
| | Adult | 2 | 2009 | 40506 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1993 | 1311 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1994 | 784 | 0.000 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1994 | 1217 | 0.000 |
Why?
| | Mutation | 1 | 2000 | 4099 | 0.000 |
Why?
| | Peptides | 1 | 1994 | 998 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2005 | 17101 | 0.000 |
Why?
|
|
Dempsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|